Switch Environment Makes U.K. A Sound Warm-up For Centralized Switch
This article was originally published in The Tan Sheet
Executive Summary
The U.K.'s bullish Rx-to-OTC switch environment can make it an attractive place to try a switch before pursuing the EU-wide centralized procedure, which contains more potential pitfalls, experts say
You may also be interested in...
OTC Oxytrol Approval In U.S. Highlights European Switch Struggles
Former McNeil Consumer Pharmaceuticals exec Stephen Mann says FDA’s approval of OTC Oxytrol poses a challenge to the EU, where Rx-to-OTC switches and the self-care movement face major obstacles. More regulators are weighing drug switches for chronic conditions, consultant Susan Coleman says.
OTC Oxytrol Approval In U.S. Highlights European Switch Struggles
Former McNeil Consumer Pharmaceuticals exec Stephen Mann says FDA’s approval of OTC Oxytrol poses a challenge to the EU, where Rx-to-OTC switches and the self-care movement face major obstacles. More regulators are weighing drug switches for chronic conditions, consultant Susan Coleman says.
OTC Oxytrol Approval In U.S. Highlights European Switch Struggles
Former McNeil Consumer Pharmaceuticals exec Stephen Mann says FDA’s approval of OTC Oxytrol poses a challenge to the EU, where Rx-to-OTC switches and the self-care movement face major obstacles. More regulators are weighing drug switches for chronic conditions, consultant Susan Coleman says.